Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | STAT3 | P40763 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17295620 | 0.81 | IDO1 (0.44) | MAPTTLR8IDO1GAANPC1 | |
| SCHEMBL16664764 | 0.81 | IDO1 (0.44) | MAPTTLR8IDO1GAANPC1 | |
| SCHEMBL28067324 | 0.81 | IDO1 (0.44) | MAPTTLR8IDO1GAANPC1 | |
| SCHEMBL4494427 | 0.81 | SMN1; SMN2 (0.44) | MAPTSMN1; SMN2TP53POLBTLR8 | |
| SCHEMBL13974490 | 0.81 | RAB9A (0.65) | MAPTSMN1; SMN2TP53POLBTLR8 | |
| SCHEMBL29767107 | 0.81 | RAB9A (0.65) | MAPTSMN1; SMN2TP53POLBTLR8 | |
| SCHEMBL2411656 | 0.80 | MEN1 (0.58) | MAPTSMN1; SMN2TP53POLBMEN1 | |
| SCHEMBL167998 | 0.80 | SMN1; SMN2 (0.56) | MAPTSMN1; SMN2MEN1LMNAKMT2A | |
| SCHEMBL27647109 | 0.79 | TLR8 (0.55) | MAPTSMN1; SMN2TP53POLBTLR8 | |
| SCHEMBL16804440 | 0.79 | MEN1 (0.50) | MAPTSMN1; SMN2TLR8IDO1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025264959-A1 | SUBSTITUTED PYRAZOLOPYRIDINES AS PHOSPHOINOSIDIDE KINASE (PIK) MODULATORS | RECURSION PHARMACEUTICALS, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| US-12312337-B2 | Compounds and methods for treating cancer | ANTIDOTE IP HOLDINGS, LLC (US) | 2025-05-27 | — | — | US | disclosed |
| US-11434245-B2 | WNT pathway modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2022-09-06 | — | — | US | disclosed |
| US-20220204482-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | ANTIDOTE IP HOLDINGS, LLC | 2022-06-30 | — | — | US | disclosed |
| EP-3966208-A2 | COMPOUNDS AND METHODS FOR TREATING CANCER | Antidote IP Holdings, LLC (US) | 2022-03-16 | — | — | EP | disclosed |
| US-20210047336-A1 | WNT PATHWAY MODULATORS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2021-02-18 | — | — | US | disclosed |
| US-10870653-B2 | WNT pathway modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2020-12-22 | — | — | US | disclosed |
| US-10870653-B2 | WNT pathway modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2020-12-22 | — | — | US | disclosed |
| WO-2020231739-A2 | COMPOUNDS AND METHODS FOR TREATING CANCER | ANTIDOTE IP HOLDINGS, LLC (US) | 2020-11-19 | — | — | WO | disclosed |
| US-20190185478-A1 | WNT PATHWAY MODULATORS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2019-06-20 | — | — | US | disclosed |
| CN-101421268-B | As the pyrazolo quinolone of effective PARP inhibitor | ABBVIE (US) | 2016-01-06 | — | — | CN | disclosed |
| WO-2015094119-A1 | WNT PATHWAY MODULATORS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015094119-A1 | WNT PATHWAY MODULATORS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-06-25 | — | — | WO | disclosed |
| US-20140213610-A1 | PYRAZOLOQUINOLONES ARE POTENT PARP INHIBITORS | ABBVIE INC. (US) | 2014-07-31 | — | — | US | disclosed |
| EP-1989204-B1 | PYRAZOLOQUINOLONES ARE POTENT PARP INHIBITORS | ABBVIE INC (US) | 2014-05-21 | — | — | EP | disclosed |
| US-8546368-B2 | Pyrazoloquinolones are potent PARP inhibitors | ABBVIE INC. (US) | 2013-10-01 | — | — | US | disclosed |
| CN-101421268-A | Pyrazoloquinolones as potent PARP inhibitors | ABBOTT LAB (US) | 2009-04-29 | — | — | CN | disclosed |
| EP-1989204-A1 | PYRAZOLOQUINOLONES ARE POTENT PARP INHIBITORS | Abbott Laboratories (US) | 2008-11-12 | — | — | EP | disclosed |
| US-20070249597-A1 | PYRAZOLOQUINOLONES ARE POTENT PARP INHIBITORS | ABBVIE INC. | 2007-10-25 | — | — | US | disclosed |
| WO-2007095628-A1 | PYRAZOLOQUINOLONES ARE POTENT PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185478-A1 | WNT PATHWAY MODULATORS | WNT1, WNT3A, WNT3 | MAPT 1812/4885SMN1; SMN2 3132/4885TP53 475/4885 |
| US-20140213610-A1 | PYRAZOLOQUINOLONES ARE POTENT PARP INHIBITORS | PARP1, PARP2, PARP3 | MAPT 2450/4885SMN1; SMN2 3231/4885TP53 222/4885 |
| US-20070249597-A1 | PYRAZOLOQUINOLONES ARE POTENT PARP INHIBITORS | PARP1, PARP2, PARP3 | MAPT 2450/4885SMN1; SMN2 3231/4885TP53 222/4885 |
| US-20220204482-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | AHR, ARNT, HMOX1 | MAPT 4304/4885SMN1; SMN2 4699/4885TP53 96/4885 |
| US-11434245-B2 | WNT pathway modulators | WNT1, WNT3A, WNT3 | MAPT 30/4885SMN1; SMN2 1527/4885TP53 331/4885 |
| US-10870653-B2 | WNT pathway modulators | WNT1, WNT3A, WNT3 | MAPT 92/4885SMN1; SMN2 2067/4885TP53 286/4885 |
| US-20210047336-A1 | WNT PATHWAY MODULATORS | WNT1, WNT3A, WNT3 | MAPT 1812/4885SMN1; SMN2 3132/4885TP53 475/4885 |
| US-12312337-B2 | Compounds and methods for treating cancer | AHR, ARNT, HMOX1 | MAPT 4304/4885SMN1; SMN2 4699/4885TP53 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.